Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT00631527
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer
- Conditions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Gruppo Italiano Carcinoma Renale
- Target Recruit Count
- 110
- Registration Number
- NCT00626509
- Locations
- 🇮🇹
Ospedale Sacro Cuore, Negrar, Italy
Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 25
- Registration Number
- NCT00620347
- Locations
- 🇰🇷
National Cancer Center, Korea, Goyang-si, Gyeonggi-do, Korea, Republic of
Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 160
- Registration Number
- NCT00619268
- Locations
- 🇫🇷
Centre Jean Perrin, Clermont Ferrand, France
🇫🇷Centre Hospitalier Universitaire de Bordeaux - Hôpital St André, Bordeaux, France
🇫🇷Centre Hospitalier Universiariare Lyon, Hôpital Lyon Sud, Lyon, France
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 32
- Registration Number
- NCT00616122
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients
- Conditions
- Interventions
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 9
- Registration Number
- NCT00617253
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Nijmegen, Netherlands
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00616109
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 191
- Registration Number
- NCT00609622
- Locations
- 🇯🇵
Pfizer Investigational Site, Chuo-ku, Tokyo, Japan
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2012-11-19
- Target Recruit Count
- 30
- Registration Number
- NCT00606008
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Phase II Sunitinib Prog Met AIPC
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 36
- Registration Number
- NCT00599313
- Locations
- 🇺🇸
Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
🇺🇸Puget Sound Cancer Center-Seattle, Seattle, Washington, United States
🇺🇸Cancer Care & Hematology Specialista of Chicagoland, Niles, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.